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Abstract
The accumulation of cholesterol in cancer cells and tumor tissues promotes cell growth,
proliferation, and migration as well as tumor progression. Cholesterol synthesis is
catalyzed by a series of enzymatic reactions. Regulation of these key enzymes can control
cholesterol synthesis and modulate cellular cholesterol levels in the cells. Meanwhile,
controlling cholesterol transportation, absorption, and depletion could also significantly
reduce cellular cholesterol levels. The current evidence supports that cholesterol
lowering agents, beyond the expected cholesterol-lowering properties, also display an
important anticancer activity in reducing cancer cell growth, proliferation and migra-
tion, and inducing apoptosis in a variety of cancer cells. Understanding the mechanisms
of cholesterol metabolism and cholesterol lowering could potentially benefit cancer
patients in cancer prevention and treatment.
Keywords: cholesterol metabolism, cholesterol-lowering agents, cancer, prevention,
therapy
1. Introduction
Cholesterol is an essential component of cellular membrane. It serves as a spacer between the
hydrocarbon chains, functions as dynamic glue during membrane assembly, and plays a
crucial role in the stability, architecture, dynamics, and function of cellular membrane [1, 2].
In addition, cholesterol is involved in vesicle trafficking and transmembrane receptor signaling
[3–6]. Meanwhile, cholesterol itself is also as a precursor of steroid hormones and sterols in the
steroidogenesis [6–8]. The vesicle trafficking, receptor-mediated signaling, and steroidogene-
sis further lead to specific biological responses and regulate different cellular functions such
as membrane biogenesis, cell growth, proliferation, apoptosis and migration, as well as tumor
progression [6–8].
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Due to the key physiological roles that cholesterol plays, the circulating and cellular cholesterol
levels in our body are tightly regulated by a physiological balance of cholesterol biosynthesis,
cholesterol catabolism, cholesterol transportation (influx and efflux), dietary cholesterol
absorption, and cholesterol depletion. Higher cholesterol, also known as hypercholesterolemia,
is a risk factor for a variety of human diseases such as cardiovascular diseases, dyslipidemia,
Alzheimer’s disease, HIV dyslipidemia, chronic inflammation, and developing diabetes. Earlier
data also indicates that accelerated cholesterol metabolism and elevated cholesterol levels
contribute to the hallmarks of cancer development and malignant transformation [9–15]. Cancer
cells need excess cholesterol and intermediates of the cholesterol biosynthetic pathway to
maintain a high level of cell growth and proliferation. Meanwhile, cholesterol is capable of
regulating multiple signaling pathways involved in carcinogenesis, cancer cell migration, and
tumor progression and is also involved in chemosensitivity and chemotherapy resistance of
cancer cells [9–19]. It is very important to understand cholesterol as an important factor
contributing to carcinogenesis and tumor progression and to elucidate the regulation of
cholesterol metabolism as a new strategy for searching cancer prevention and therapy drugs.
2. Cell biology of cholesterol
2.1. De novo cholesterol biosynthesis
Cholesterol is a 27-carbon and tetracyclic ring steroid that is catalyzed by a series of more than
26 separate enzymatic reactions in several subcellular compartments [20, 21]. The de novo
biosynthesis can be considered as five major steps: (1) From acetyl-CoA to 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA): the acetyl-CoA can be derived from the oxidation of
fatty acids or synthesized from cytosolic acetate precursors (metabolites or taken up from
dietary or exogenous sources), and three acetyl-CoAs condense to form acetoacetyl-CoA by
acetoacetyl-CoA acetyltransferases or thiolase and then HMG-CoA by HMG-CoA synthase. (2)
The formation of mevalonate: HMG-CoA is reduced to mevalonate by HMG-CoA reductase, a
rate-limiting and irreversible step in the metabolic pathway that produces cholesterol and other
isoprenoids. (3) From mevalonate to isopentenyl pyrophosphate (IPP): mevalonate is further
converted to IPP through two phosphorylation steps and one decarboxylation step. This
conversion is involved in seven different enzymes (mevalonate-3-kinase, mevalonate-5-kinase,
mevalonate-3-phosphate-5-kinase, phosphomevalonate kinase, mevalonate-5-phosphate
decarboxylase, mevalonate pyrophosphate decarboxylase, and isopentenyl phosphate kinase)
via different avenues. (4) From IPP to squalene: three molecules of IPP further condense to form
a farnesyl pyrophosphate (FPP) and two molecules of FPP then condense to form squalene. The
enzymes involved in the process are IPP isomerase, farnesyl-diphosphate synthase, and
squalene synthase. (5) From squalene to lanosterol to cholesterol: the oxidation of squalene by
squalene epoxidase forms 2,3-oxidosqualene which is further cyclized to lanosterol by squalene
oxidocyclase. Lanosterol is finally converted to cholesterol by a series of demethylations,
desaturations, isomerizations, and reductions. Demethylation reactions produce zymosterol as
an intermediate and further converted to cholesterol by at least two pathways that differ in the
order of the desaturations, isomerizations, and reductions (Figure 1) [22–27].
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Figure 1. Scheme of the cholesterol biosynthesis pathway. (1) Thiolases or acetyl-coenzyme A acetyltransferases, (2) hy-
droxy-3-methylglutaryl-CoA synthase, (3) hydroxy-3-methylglutaryl-CoA reductase, (4) mevalonate-3-kinase or me-
valonate-5-kinase, (5) mevalonate-3-phosphate-5-kinase or phosphomevalonate kinase, (6) mevalonate-5-phosphate
decarboxylase, (7) mevalonate pyrophosphate decarboxylase, (8) isopentenyl phosphate kinase, (9) isopentenyl pyro-
phosphate isomerase, (10) farnesyl-diphosphate synthase, (11) squalene synthase, (12) squalene monooxygenase or
squalene epoxidase, and 19 reactions are included multiple demethylations, desaturations, isomerizations, and reduc-
tions.
2.2. Cholesterol homeostasis
Cholesterol is a vital lipid and plays well-described biochemical roles and diverse functions at
cellular level [1–3]. The homeostasis of cholesterol is among the most intensely regulated
processes in our body. High cholesterol is a risk factor to numerous pathologies such as
cardiovascular disease, atherosclerosis, dyslipidemia, and neurodegenerative diseases and is
associated with the development of diabetes and cancer. Cholesterol homeostasis is achieved
through intricate mechanisms involving biosynthesis, catabolism, dietary absorption, trans-
portation (influx or efflux), and depletion (Figure 2) [28–32]. Slightly less than half of cholesterol
in our body derives from de novo biosynthesis every day. The liver is the dominant site of
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cholesterol biosynthesis, and in vivo liver cholesterol production has been estimated at 1–2 g/
day. Cholesterol is synthesized in liver and then secreted as circulating lipoproteins into
bloodstream. The intestine and skin are also very important for cholesterol synthesis [33–35].
Although the majority of cholesterol sources comes from cholesterol biosynthesis, it is under
feedback regulation. The absorption of cholesterol mainly derives from three sources: diet, bile,
and intestinal epithelial sloughing. The average intake of cholesterol in the Western diet is
approximately 300–500 mg per day. Bile is estimated to contribute nearly 800–1200 mg of
cholesterol per day to the intraluminal pool. A third source of intraluminal cholesterol comes
from the turnover of intestinal mucosal epithelium, which provides roughly 300 mg of choles-
terol per day [36]. In cholesterol catabolism, the conversion of cholesterol into excretable bile
acids represents the most relevant mechanism of irreversible elimination of cholesterol from the
body, which plays a key role in hepatic and systemic cholesterol homeostasis. Under physio-
logical conditions, approximately 300–400 mg of cholesterol is disposed in the liver daily [37].
Because peripheral cells do not catabolize the cholesterol molecule, there are two distinct
mechanisms for maintaining cellular cholesterol homeostasis. One is the nonspecific classical
pathway mediated by physicochemical diffusion of cholesterol through the aqueous phase and
the other is cholesterol esterification on high-density lipoprotein (HDL) by lecithin: cholesterol
acyltransferase reaction [38, 39]. The reaction is initiated by the interaction of lipid-free or lipid-
poor apolipoproteins with cellular surface resulting in the assembly of HDL particles with
phospholipid and cholesterol as well as extracellular cholesterol esterification mainly on HDL
[40]. Furthermore, changing dietary style to control cholesterol absorption and using pharma-
ceutical drugs to inhibit several key enzymes in cholesterol synthesis can also significantly
reduce the level of cellular cholesterol. All of these pharmaceutical drugs and dietary style have
been commonly used for keeping a healthy life and preventing heart disease [41–44].
Figure 2. Cholesterol homeostasis and functions. Cholesterol homeostasis is tightly regulated in our body and can be
achieved through intricate mechanisms involved in biosynthesis, dietary absorption, transportation (influx or efflux),
catabolism, and depletion. The functions of cholesterol are composed of distinct membrane, control membrane fluidity
and protein recruitment, produce steroid and oxysterol, and are involved in cell signaling to regulate cell growth, pro-
liferation, and migration.
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2.3. Biological functions of cholesterol
Disruption to cholesterol homeostasis leads to a variety of diseases such as coronary heart
disease, atherosclerosis, and metabolic syndrome as well as cancer [9–19, 45–51]. This indicates
that cholesterol plays a crucial role in the regulation of cellular function (Figure 2). In the cells,
cholesterol is mandatory for cellular growth and serves as one of the necessary building blocks
for new membranes demanded by dividing cells during proliferation. Cell membranes have
been recognized as heterogeneous structures composed of distinct membrane microdomains
with different proteins and lipids. Lipid rafts, cholesterol-rich domains, play an important
platform as a signaling station for many cellular processes, including membrane sorting and
trafficking, cell polarization, and signal transduction [52–56]. Cholesterol promotes cell
proliferation by inducing the activation of the AKT and/or the ERK signaling pathway as well
as Ca2+ channel [57–60] and cell migration by increasing the activity of calpain that is also
Ca2 + dependent [61, 62] and is also involved in Hedgehog processing, diffusion, and reception
[63, 64]. Cholesterol can be converted to steroid hormones which activate nuclear receptors
and thus help to control metabolism, inflammation, immune functions, salt and water balance,
the development of sexual characteristics, and the ability to withstand illness and injury [65,
66]. Meanwhile, the metabolites of cholesterol such as hydroxycholesterols play multiple
biological functions in the body [67, 68]. Cholesterol also contributes to chemotherapy
resistance which leads to treat failure [11–14]. Taken together, cholesterol is tightly associated
with cancer cell growth, proliferation and therapy.
3. The balance of cholesterol and cancer
Cholesterol accumulation in cancer cells and tumor tissues was discovered in cancer cells and
tumor tissues started in earlier 1900s [12, 69, 70]. Since then, researchers have studied the
relationship between cellular cholesterol and cancer in depth. Recent epidemiological studies
suggest the correlation between serum cholesterol level and the risk of certain types of cancer
[15, 71–74]. It is difficult to draw conclusions from epidemiological studies on whether
cholesterol is a key factor of cancer incidence because of of their intrinsic limitations. On the
other hand, experimental evidence from cell and animal models indicates that cholesterol plays
a promotional role in cancer cell growth and cancer development and progression [57–60].
These findings support the notion that lowering cholesterol level may be a useful and effective
strategy for cancer prevention and a therapeutic potential for cancer treatment.
3.1. Lowering cholesterol level
As described above, cholesterol homeostasis is controlled by its biosynthesis, catabolism,
dietary absorption, transportation, and depletion [28–32]. Among these, cholesterol biosyn-
thesis and absorption with low-density lipoprotein (LDL) receptor (LDLR) which mediates the
endocytosis of cholesterol-rich LDL are key to elevate cellular cholesterol. By contrast, there
are also two common avenues to achieve cholesterol lowering: (1) pharmacological treatment
which inhibits cholesterol biosynthesis [41–45] and (2) dietary control that reduces cholesterol
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absorption [36, 75]. Meanwhile, cholesterol metabolite, 27-hydroxycholesterol, and other
oxysterols can activate the liver X receptors (LXR), resulting in a reduction of intracellular
cholesterol [76–78]. Modulation of LXR and their downstream targets has appeared to be
involved in cholesterol and lipid metabolism in response to changes in cellular cholesterol
status [76–78]. This also draws attention to the therapeutic interest of developing LXR agonists
as a bona fide therapeutic approach in cancer treatment. The cross talk of LDLR-SREBP (sterol
regulatory element-binding protein) signaling and LXR signaling in the regulation of choles-
terol metabolism is potential as a new strategy to develop cancer therapeutic drugs and
treatment regimen.
3.2. Cholesterol-lowering drugs
There are many different agents that can inhibit cholesterol biosynthesis at different enzymatic
steps or reduce cholesterol level by different regulation pathways. Table 1 summaries the
targets and effects of different cholesterol-lowering agents. Statins, first marketed in 1987, are
the most common drugs to lower cholesterol level. As structural analogues of HMG-CoA,
statins inhibit HMG-CoA reductase to block the conversion of HMG-CoA to mevalonic acid
in a rate-limiting step of cholesterol biosynthesis. Up to date, a number of different compounds
in this class drugs have been developed: atorvastatin (Lipitor), cerivastatin (Baycol; withdrawn
from the market in 2001), fluvastatin (Lescol), lovastatin (Mevacor), mevastatin (Compactin),
pitavastatin (Livalo), pravastatin (Pravachol or Selektine), rosuvastatin (Crestor), and simvas-
tatin (Zocor). They are effective for treating cardiovascular disease, atherosclerosis, dyslipo-
proteinemia, and liver disease [79–81] and are also recommended for those who do not meet
their lipid-lowering goals through diet and lifestyle changes. Statins are also considered as an
anticancer agent to prevent and treat cancer patients [42–44]. Because of multiple side effects
of statins, such as muscle pain, increased risk of diabetes mellitus, and abnormalities in liver
enzyme tests, many other enzymes that are involved in cholesterol biosynthetic pathway
beyond HMG-CoA reductase are also being considered as targets for developing cholesterol-
lowering drugs. These drugs include bisphosphonates which inhibit farnesyl-diphosphate
synthase [82] and lonafarnib (SCH66366) and tipifarnib (R115777) which inhibit farnesyltrans-
ferase [83]. YM-53601, RPR-107393, and TAK-475 (Lapaquistat) can inhibit squalene synthase
[84–86], and Ro 48-8071, BIBB515, and terbinafine (Lamisil) are potent inhibitors of 2,3-
oxidosqualene cyclase or squalene epoxidase [87–89]. These agents are used in clinic and in
clinic trials.
In addition, several another classes of compounds which can lower cholesterol level via
different molecular mechanisms have recently been developed. Ezetimibe (Zetia), a cholesterol
uptake-blocking drug, prevents cholesterol absorption from dietary intake [90]. Fibrate drugs
(Gemfibrozil, Tricor, Atromid-S), an activator of peroxisome proliferator-activated receptor α
(PPARα), can reduce very-low-density lipoprotein (VLDL) - and LDL-containing apoprotein
B and increase HDL-containing apoprotein AI and AII [91, 92]. Cholestyramine, colestipol, and
colesevelam, bile acid sequestrants, can remove bile acids from the body and further convert
more plasma cholesterol to bile acids to reduce cholesterol level [93, 94]. Some other choles-
terol-lowering agents are also on the market or available for research. Acyl-CoA:cholesteryl
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acyltransferase inhibitor (avasimibe or CI-1011) induces cholesterol 7-α-hydroxylase and
increases bile acid synthesis [95]. Green tea or catechins can inhibit the intestinal absorption
of dietary lipids [96]. Lomitapide (Juxtapid) inhibits the microsomal triglyceride transfer
protein required for VLDL assembly and secretion [97]. Mipomersen is a second-generation
antisense oligonucleotide targeted to human apolipoprotein B-100 which is the structural core
of LDL cholesterol [98]. Anacetrapib is a novel inhibitor of cholesteryl ester transfer protein
[99]. Evolocumab (AMG145) and alirocumab are monoclonal antibodies which inactivate the
proprotein convertase subtilisin/kexin type 9 (PCSK9) and lower LDL level [100, 101]. Dyna-
sore reduces labile cholesterol in the plasma membrane [102]. Some of these cholesterol-
lowering drugs have demonstrated their anticancer property and have the potential of cancer
pharmacological prevention [41–45].
Agents Targets Effects References
Statins HMG-CoA reductase Block the conversion of HMG-CoA to mevalonic acid [79–81]
Bisphosphonate FPP synthase Attenuate the formation of FPP [82]
SCH66366
R115777
Farnesyltransferase Reduce adding a farnesyl group to proteins [83]
YM-53601
RPR-107393
TAK-475
Squalene synthase Inhibit the conversion of FPP to squalene [84–86]
Ro 48-8071 2,3-Oxidosqualene
synthase
Block the formation of 2,3 oxidosqualene [87, 88]
BIBB515
Terbinafine
Squalene epoxidase
Ezetimibe
Catechins
Cholesterol
absorption
Block cholesterol uptake in the small intestine [89, 90]
Gemfibrozil
Tricor
Atromid-S
PPARα Reduce VLDL and LDL level [91, 92]
Cholestyramine
Colesevelam and the
conversion of cholesterol
to bile acid
Colestipol
Bile acid sequestrants Increase bile acid removal [93, 94]
Avasimibe
CI-1011
ACAT Increase cholesterol oxidation and bile acid synthesis [95, 96]
Lomitapide Triglyceride transfer
protein
Reduce VLDL assembly and secretion [97]
Mipomersen Apolipoprotein B-100 Reduce LDL level [98]
Evolocumab
Alirocumab
PCSK9 antibody Inactivate PCSK9 and lower LDL level [99, 100]
Dynasore Dynamin Reduce membrane cholesterol [101]
*PPARα, peroxisome proliferator-activated receptor α; ACAT, Acyl-CoA:cholesteryl acyltransferase.
Table 1. Targets and effects of different cholesterol-lowering agents.
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3.3. Anticancer property of cholesterol-lowering drugs
Accumulating evidence supports that deregulation of any steps in cell growth, proliferation,
and migration may result in cell malignant transformation. More than a century ago, choles-
terol was observed to accumulate in malignant tissues [69]. Now, more and more evidence
shows that cholesterol plays a critical role in the regulation of cancer cell growth and prolif-
eration and tumor progression [8, 10–18, 70]. The key regulators in cholesterol metabolism
attract many researchers around the world to search for novel anticancer agents. Based on
cholesterol biofunctions and experimental data, the role of cholesterol-lowering drugs may
not limit on the property of LDL-cholesterol lowering but may also be involved in the pre-
vention or treatment of cancer. Statins are the most common cholesterol-lowering drugs and
are also the most studied drugs. Whether statins exhibit anticancer properties is based on
experimental studies, epidemiological studies, and clinical studies. In experimental studies,
statins reduce a variety of cancer cell viability (Figure 3) [75, 103–105]. The epidemiologic data
also support that statins reduce the incidence of gastric cancer, breast cancer, advanced prostate
cancer, colorectal cancer, and cholangiocarcinoma [105–109]. However, there are also some
studies that do not support the association of statin use with cancer risk [110, 111]. In clinical
studies, statins can significantly reduce prostate cancer-specific mortality and reduce the risk
of biochemical recurrence among the patients treated with radiation therapy [112] and are also
associated with improved survival in patients with metastatic renal cell carcinoma [113]. So
far, statins show some promising results in certain types of cancer. The potential of statins in
modern cancer prevention and treatment is very promising. Meanwhile, it is also important
to search other cholesterol-lowering agents that are more effective and reduce adverse side
effects. Some of these agents have already been studied at the different stages [89, 114].
Figure 3. Treatment of lovastatin reduces cell viability in different cancer cell lines. Different cancer cells were cultured
in 96-well plates and treated with 10 μM lovastatin for 3 days; the samples analyzed cell viability by MTT assay
(n = 16). The values of lovastatin treatment were statistically different from the controls. P < 0.05. M231, MDA-MB-231.
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3.4. Molecular mechanism of anticancer properties of cholesterol-lowering drugs
Expression of HMG-CoA reductase gene can be regulated by genetic or dietary interaction
[115], in which it is transcriptionally regulated by endoplasmic reticulum-based transcription
factor, SREBP-2 [116], or high-fat diet feeding [117]. Statins inhibit HMG-CoA reductase to
block cholesterol biosynthesis which attenuate cell proliferation and arrest cell cycle progres-
sion by interrupting growth-promoting signals and involving in RAS/RAF/MEK/ERK,
PI3K/AKT/mTOR and Wnt/β-catenin signaling cascades [118, 119]. Statins also selectively
induce proapoptotic potential in tumor cells and synergistically enhance proapoptotic
potential of several cytotoxic agents. The mechanism for this effect has been demonstrated by
disrupted binding of RhoA inhibitor GDIα which leads to increased levels of GTP-bound forms
of RhoA, Rac1, and cdc42 proteins.These proteins induce apoptosis 1) by suppression of anti-
apoptotic proteins such as Bcl2 or activation of the superoxide-activated JNK pathway [120]
or 2) by inhibiting Akt/mTOR pathway and inducing programmed cell death 4 expression in
renal cell cancer cells [121]. Statins alter the angiogenic potential of cells by modulating
apoptosis inhibitory effects of VEGF and decrease secretion of metalloproteases and suppress
the rate of activation of multiple coagulation factors and thus prevent coagulation-mediated
angiogenesis [122]. Statins suppress the Rho/Rho-associated coiled-coil-containing protein
kinase pathways, thereby inhibiting cell migration, invasion, adhesion, and metastasis [123].
Other cholesterol-lowering agents have not been widely studied as statins. However, all
cholesterol-lowering agents could affect membrane composition, in particular cholesterol-rich
domain, termed lipid rafts. Membrane lipid rafts are highly ordered membrane domains that
are enriched in cholesterol, sphingolipids, and gangliosides and selectively recruit certain
classes of proteins (a large number of cancer-related signaling and adhesion molecules) and
act as major modulators of membrane geometry, lateral movement of molecules, and traffic
and signal transduction [52, 54]. Cholesterol-lowering drugs lead to membrane cholesterol
depletion which could disrupt membrane lipid rafts, block the adhesion and migration
processes of cancer cells, and induce cancer cell apoptosis [124, 125].
4. Cholesterol-lowering drugs in cancer prevention and therapy
A growing body of evidence from cell biology and animal models has strongly demonstrated
the anticancer activity of cholesterol-lowering drugs such as statins [7, 83–89, 104–108].
Epidemiological studies also suggest an anticancer effect of statins evidenced by the reductions
of cancer incidence and cancer-related mortality, although the association between statin use
and cancer incidence based on different cancer remains controversial from different laborato-
ries around the world. Statins as part of pharmacological cancer prevention and chemotherapy
have generated interest in the oncology community and have been investigated in a variety of
cancers at early and late stages and in the combination with chemotherapy and radiation
therapy. Here, we summarize the current data that statin use affects cancer incidence and
therapy.
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Study No. of subjects/
studies
Results References
Bonovas, 2008 12 studies No significant relationship between statins and pancreatic cancer risk [129]
Khurana, 2007 483,733 Protective against the development of pancreatic cancer [130]
Lin, 2016 19,727 Prevent H. pylori-associated gastric cancer [105]
Singh, 2013 11 studies Prevent gastric cancer risk in both Asian and Western population [131]
Tsan, 2012 33,413 Reduce the risk for hepatocellular carcinoma in HBV-infected patients [132]
Chen, 2015 2,053 Decrease hepatocellular carcinoma in diabetic patients [133]
Zhang, 2013 13 studies No association between statin use and risk of bladder cancer [134]
Peng, 2015 3,174 Reduce the risk of cholangiocarcinoma [108]
Yi, 2014 20 studies Preventive effects against hematological malignancies [135]
Pradelli, 2015 14 studies Negatively associated with all hematological malignancies [136]
Wang, 2013 20 studies Nonsignificant association between statin users and lung cancer risk [137]
Bansal, 2012 27 studies Reduce the risk of total and advanced prostate cancer [138]
Jacobs, 2007 55,454 Reduce the risk of advanced prostate cancer [109]
Undela, 2012 24 studies Do not support that statins have a protective effect against breast
cancer
[139]
Lytras, 2014 40 studies Do not support that statin users reduce the risk of colorectal cancer [140]
Setoguchi, 2007 24,439 No effect in the risk of colorectal, lung, or breast cancer in older
patients
[141]
Kuoppala, 2008 42 studies No effect on the incidence of lung, breast, or prostate cancer
Protect from stomach and liver cancer and from lymphoma
Increase the incidence of both melanoma and nonmelanoma skin
cancer
[142]
Table 2. Effect of statins on cancer incidence.
4.1. Cholesterol-lowering drugs in cancer prevention
Cholesterol is accumulated in different solid tumors and cancer cells [12, 69–71, 126, 127],
raising questions concerning the role of cholesterol in cancer cell growth, proliferation, and
migration as well as tumor progression [57–61]. Although cholesterol-lowering drugs have
also been shown to possess an important antitumor activity that reduces cell growth, prolif-
eration, and migration through ERK-mediated and Akt-mediated signaling pathways and is
capable of inducing apoptosis through extrinsic and intrinsic pathways using different cancer
cells as models [43–45, 75, 78, 104, 118–123], it is still unclear whether statins are suitable to
prevent the incidence of cancer. More than a hundred of epidemiological studies around the
world have been performed to evaluate the effect of statin on the risk of cancer incidence [105,
108, 109, 126–142]. These studies have been focused on statin type, potency, lipophilic or
hydrophobicity status, and duration of use. Due to the limitation of epidemiological studies
with the patients different in age, sex, living regions, and life style, the results are controversial.
Table 2 summarizes the association of cancer risk and statin use in pancreatic cancer, gastric
cancer, liver cancer, lung cancer, bladder cancer, breast cancer, prostate cancer, colorectal
cancer, blood cancer, and other malignancies. The clinical studies have provided conflicting
Cholesterol Lowering Therapies and Drugs116
data regarding whether statins may reduce or may be no effect on the risk of cancer. It is clear
that current data cannot rule out the association of statin use with the risk of some cancers.
Analyses of larger numbers of cases, subgroup design (participant ethnicity or confounder
adjustment), randomized controlled trials, and high-quality cohort studies with longer
duration of follow-up are needed to further confirm this association. Meanwhile, we also need
to study cancer patient genetic mutations and determine whether the effect of statins on cancer
prevention and therapy is associated with genetic mutation. It is clear that defining the
underlying mechanisms of how cholesterol lowering contributes to cancer prevention and the
search for other cholesterol-lowering agents with better outcome has emerged as future
objectives. Whether cholesterol-lowering agents are used in cancer prevention will be based
on the analysis of responses to these agents with cancer patient genetic information.
4.2. Cholesterol-lowering drugs in cancer treatment
Cholesterol is implicated in various cellular processes including the involvement of cell
proliferation/apoptosis balance regulation in various types of cancers. Statins and other
cholesterol-lowering agents are very common and effective medication used in preventing
heart disease in those with high cholesterol, but no history of heart disease. The anticancer
activity of these drugs has also attracted oncologists to consider whether cholesterol-lowering
drugs can be a tool for cancer treatment. A variety of studies have focused on the effect of
statins alone or in combination with other chemo- or/and immune-therapeutic drugs or
radiation therapy on the treatment of different cancer patients. McKay et al. [113] showed some
promising data that statin use improved survival in patients with metastatic renal cell
carcinoma. Raval et al. found that statin significantly reduced the prostate cancer-specific
mortality and improved the biochemical recurrence in certain subgroup of men with prostate
cancer [112]. Song et al. found that statin use also reduces biochemical recurrence in men with
prostate cancer after radical prostatectomy [143]. Statin use is related to reductions in overall
and cancer-specific mortality [144] and associated with longer rates of survival [145] in
colorectal cancer survivors. Two recent studies indicate that statin use is associated with
improved overall survival in patients with resectable pancreatic ductal adenocarcinoma [146,
147]. Statin use also improves overall survival among patients undergoing resection for
pancreatic cancer [148]. Lipophilic statins are associated with a reduced risk of breast cancer
recurrence and inflammatory breast cancer [149]. Because statins negatively interfere with
CD-20 and rituximab-mediated activity, statins have a negatively effect on clinical outcome in
patients with rituximab-treated leukemia [150]. No association of statin use with patient
survivals was also reported from colorectal cancer study [151]. Future studies are needed to
further evaluate which cancer patients may benefit from statin treatment, what the best
treatment is, and which cholesterol-lowering drugs are better to use in cancer treatment.
5. Concluding remarks and future perspectives
Cholesterol is tightly regulated by a physiological balance of cholesterol metabolism (biosyn-
thesis and degradation), dietary absorption, transportation (efflux and influx), and depletion.
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Importantly, cholesterol is accumulated in cancer cells and tumor tissues and is implicated in
various cellular processes including cell growth, proliferation, and migration. The increase and
decrease in cellular and circulating cholesterol levels have demonstrated the involvement of cell
proliferation/apoptosis balance regulation. This chapter reviewed our current understanding
of how cholesterol metabolism contributes to cancer development and progression and
cholesterol-lowering drugs may be associated with the therapeutic potential of cancer preven-
tion and treatment. Current evidence cannot exclude the relevance of cancer risk with statin use
as seen in a variety of studies. Whether the genetic mutations of cancer patients are associated
with the response of statins is also unknown. It is clear that more studies are needed to better
characterize potential statin-mediated mechanisms that prevent cancer incidence. On the other
hand, statins alone or used in combination with certain anticancer drugs or radiation therapy
can improve survival in patients with several different tumors. Further research using large
cohort studies in different cancers is needed to clarify these issues. In addition, searching for
novel classes of cholesterol-lowering drugs with more effects and less side effects could provide
new therapeutic options for cancer prevention and therapy.
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